CONTENT VALIDATION AND DISCLOSURES
Research To Practice is committed to providing its participants with high-quality, unbiased and state-of-
the-art education. We assess potential conflicts of interest with faculty, planners and managers of
CME activities. Real or apparent conflicts of interest are identified and resolved by a peer review content
validation process. The content of each activity is reviewed by both a member of the scientific staff
and an external independent reviewer for fair balance, scientific objectivity of studies referenced and
patient care recommendations.
The scientific staff and consultants for Research To Practice are involved in the development and
review of content for educational activities and report the following real or apparent conflicts of interest
for themselves (or their spouses/partners) that have been resolved through a peer review process:
Richard Kaderman, PhD, Neil Love, MD, Mary Beth Nierengarten, Douglas Paley, Michelle Paley, MD,
Margaret Peng, Lilliam Sklaver Poltorack, PharmD, Chris Thomson, MD, MS and Kathryn Ault Ziel, PhD
— no real or apparent conflicts of interest to report; Marie Bialek, PharmD — freelance/contractor:
McNeil Consumer & Specialty Pharmaceuticals, Janssen Pharmaceutica Products LP, Salary
(spouse): AstraZeneca Pharmaceuticals LP; Sally Bogert, RNC, WHCNP — shareholder of Amgen
Inc. Research To Practice receives education grants from Abraxis Oncology, Amgen Inc, AstraZeneca
Pharmaceuticals LP, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Biogen Idec,
Genentech BioOncology, Genomic Health Inc, OSI Pharmaceuticals, Roche Laboratories Inc and
Sanofi-Aventis, who have no influence on the content development of our educational activities.
In addition, the following faculty (and their spouses/partners) have reported real or apparent conflicts
of interest that have been resolved through a peer review process:
Dr Chu — Consulting Fees: BMS-ImClone, Genentech BioOncology, Roche Laboratories Inc, Sanofi-Aventis. Dr Wolff — Consulting Fees: Eli Lilly and Company, Pfizer Inc. Dr Burris — Consulting Fees: Genentech
BioOncology, Novartis Pharmaceuticals; Fees for Non-CME Services Received Directly from Commercial Interest
or their Agents: Sanofi-Aventis.
This educational activity contains discussion of published and/or investigational uses of agents that are
not indicated by the Food and Drug Administration. Research To Practice does not recommend the use
of any agent outside of the labeled indications. Please refer to the official prescribing information for each
product for discussion of approved indications, contraindications and warnings. The opinions expressed
are those of the presenters and are not to be construed as those of the publisher or grantors.
